Abstract
First-in-human clinical studies (phase I) of new anticancer agents have traditionally focused on determining the maximum tolerated dose and dose-limiting toxicities in patients with cancer. Subsequent phase II and III trials evaluate whether the new agent has potential efficacy. This process is time consuming, expensive, involves potentially hundreds of patients, and has a high rate of failure. To address some of these limitations and facilitate the development and approval of new drugs, the FDA allows phase 0 first-in-human trials to establish whether the investigational agent achieves the desired concentrations and/or modulates its target at clinically achievable concentrations. These trials administer subtherapeutic doses of drug, which are not anticipated to cause toxicity, to a small number of patients for the conduct of pharmacodynamic, pharmacokinetic, or imaging studies. If the agent demonstrates a desirable pharmacokinetic/pharmacodynamic profile, traditional phase I safety and tolerability studies are conducted; otherwise, further clinical development of the agent is unlikely to be justified. This chapter summarizes the key differences between phase 0 and phase I clinical trials.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Agulnik M, Oza AM, Pond GR et al (2006) Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. J Clin Oncol 24:4801–4807
Baker AF, Dragovich T, Ihle NT et al (2005) Stability of phosphoprotein as a biological marker of tumor signaling. Clin Cancer Res 11:4338–4340
Collins JM (2008) Phase 0 clinical studies in oncology. Clin Pharmacol Ther 85:204–207
DiMasi JA, Grabowski HG (2007) Economics of new oncology drug development. J Clin Oncol 25:209–216
Donawho CK, Luo Y, Luo Y et al (2007) ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 13:2728–2737
Doroshow JH, Parchment RE (2008) Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient. Clin Cancer Res 14:3658–3663
Dowlati A, Haaga J, Remick SC et al (2001) Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. Clin Cancer Res 7:2971–2976
Gutierrez M, Collyar D (2008) Patient perspectives on phase 0 clinical trials. Clin Cancer Res 14:3689–3691
Helft PR, Daugherty CK (2006) Are we taking without giving in return? The ethics of research-related biopsies and the benefits of clinical trial participation. J Clin Oncol 24:4793–4795
Hidalgo M, Eckhardt SG (2001) Matrix metalloproteinase inhibitors: how can we optimize their development? Ann Oncol 12:285–287
Kelloff GJ, Krohn KA, Larson SM et al (2005) The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 11:7967–7985
Kinders R, Parchment RE, Ji J et al (2007) Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. Mol Interv 7:325–334
Kinders RJ, Hollingshead M, Khin S et al (2008) Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts. Clin Cancer Res 14:6877–6885
Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–715
Kummar S, Kinders RJ, Rubinstein L et al (2007) Compressing drug development timelines in oncology using phase ‘0’ trials. Nat Rev Cancer 7:131–139
Kummar S, Rubinstein L, Kinders R et al (2008) Phase 0 clinical trials: conceptions and misconceptions. Cancer J 14:133–137
Kummar S, Doroshow JH, Tomaszewski JE et al (2009) Phase 0 clinical trials: recommendations from the task force on methodology for the development of innovative cancer therapies. Eur J Cancer 45:741–746
Kummar S, Kinders R, Gutierrez ME et al (2009) Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 27:2705–2711
Moore MJ, Hamm J, Dancey J et al (2003) Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21:3296–3302
Robinson WT (2008) Innovative early development regulatory approaches: expIND, expCTA, microdosing. Clin Pharmacol Ther 83:358–360
Rubinstein LV, Steinberg SM, Kummar S et al (2010) The statistics of phase 0 trials. Stat Med 29:1072–1076
US Food and Drug Administration (2004) Innovation or stagnation? Challenge and opportunity on the critical path to new medical products. http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4079B1_05_Topic3-TabB.pdf. Accessed 4 Nov 2009
US Food and Drug Administration (2006a) Guidance for industry, investigators, and reviewers: exploratory IND studies. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM078933.pdf. Accessed 4 Nov 2009
US Food and Drug Administration (2006b) Guidance for industry: INDs – approaches to complying with CGMP during phase 1. http://www.fda.gov/ohrms/DOCKETS/98fr/05d-0286-gdl0001.pdf. Accessed 4 Nov 2009
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Disclaimer: The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Kummar, S., Doroshow, J.H. (2014). Phase 0 Trials in Oncology. In: Rudek, M., Chau, C., Figg, W., McLeod, H. (eds) Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Cancer Drug Discovery and Development. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9135-4_5
Download citation
DOI: https://doi.org/10.1007/978-1-4614-9135-4_5
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-9134-7
Online ISBN: 978-1-4614-9135-4
eBook Packages: MedicineMedicine (R0)